Type 2 Diabetes Trial, Recruiting NCT06999356 Sponsor: Sutter Health Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06999356
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with Type 2 diabetes
  • People whose most recent HbA1c blood sugar test result was 9% or higher, tested within the last 6 months
  • People who agree to use only the glucose monitoring device provided by the study to track their blood sugar levels during the trial

Who may not be able to join:

  • People who have Type 1 diabetes
  • People who currently use insulin
  • People who are pregnant
  • People who take steroids or other medications known to affect blood sugar levels, including certain antipsychotic medications (such as Clozapine, Olanzapine, Paliperidone, Quetiapine, or Risperidone), corticosteroids, immune-suppressing medications (such as Cyclosporine, Sirolimus, or Tacrolimus), or HIV medications known as protease inhibitors (such as Atazanavir, Darunavir, Fosamprenavir, Indinavir, Nelfinavir, Ritonavir, Saquinavir, or Tipranavir)
  • People with a life expectancy of less than 6 months
  • People who have been diagnosed with stage 5 kidney disease, or who the trial doctor considers to be at risk of needing dialysis
  • People with any active, serious health condition that the trial doctor believes could interfere with taking part in the study
  • People who the trial doctor believes would be unable to follow the study procedures (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Kerr, PhD, Sutter Health

Phone: 805-624-8688

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sutter Health
Registry
ClinicalTrials.gov
Start date
22 May 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in HbA1c at 18 weeks compared to baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov